TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

AstraZeneca to stay independent, 'strong'

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

By The Associated Press
Wednesday, May 7, 2014, 12:01 a.m.
 

LONDON — AstraZeneca on Tuesday outlined plans to make sales jump during the next decade, an effort to persuade shareholders the drugmaker can do well as an independent company rather than get bought out by rival Pfizer.

In a statement, AstraZeneca said investors would share the benefits of a “strong and consistent revenue growth” in which annual sales would rise to more than $45 billion by 2023 from $25.7 billion last year.

The Britain-based company on Friday spurned Pfizer's third acquisition proposal, this time for about $106 billion. AstraZeneca PLC, the No. 8 drugmaker, called that inadequate and said the potentially lucrative “pipeline” of new drugs it is developing would be disrupted by a takeover.

AstraZeneca's revenues last year fell 6 percent, but the company said Tuesday that under its new management and strategy, it is now “repositioned for a return to growth.”

“AstraZeneca is completing its transformation and now has the right size, focus and team to deliver on one of the most exciting pipelines in the pharmaceutical industry,” Chief Executive Pascal Soriot said. “We are continuing to create significant value for shareholders from our independent strategy.”

Pfizer said last week it was considering its options. If the deal succeeds, it would be the biggest takeover in British corporate history. Many politicians fear it could mean big job cuts and a loss of stature in the country's science sector.

On Tuesday, Business Secretary Vince Cable told lawmakers he will not rule out intervening in any formal bid by Pfizer to buy AstraZeneca, although he stressed that the shareholders of both companies make the ultimate decision.

“We see the future of the U.K. as a knowledge economy, not as a tax haven,” he said, referring to concerns that Pfizer could benefit from tax advantages should it acquire AstraZeneca.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Energy sector adjusts to global oil plummet
  2. Drought opens Texas ranchers’ eyes to income options
  3. Kim Komando: Can you get a virus on your smartphone?
  4. Coal ash sites have tainted hundreds of waterways, aquifers
  5. Diane Stafford: Consider digital footprint
  6. 3 tips to use up health account funds
  7. ‘Staff Pick’ is golden ticket on Kickstarter
  8. Makers of wine corks have lost ground to screw tops
  9. Real estate union: Howard Hanna buys Langholz Wilson Ellis
  10. As smokers seek Cuban cigars, retailers point to trade embargo
  11. EPA says it won’t regulate coal ash as hazardous waste
Subscribe today! Click here for our subscription offers.